NCT04389723 is a NA clinical trial of Qualia Mind in Healthy, sponsored by Neurohacker Collective.

Who is sponsoring NCT04389723?

NCT04389723 is sponsored by Neurohacker Collective.

What drugs are being tested in NCT04389723?

Interventions in NCT04389723: Qualia Mind, Placebo.

What condition does NCT04389723 study?

NCT04389723 studies Healthy, Cognitive Function.

Is NCT04389723 still recruiting?

NCT04389723 is currently completed. Last updated 9 October 2020.

Last reviewed 2020-10-09 · How we verify

NCT04389723

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy Study of Qualia Mind on Cognition in a Healthy Population

Completed NA Last updated 9 October 2020

What this trial tests

NA trial testing Qualia Mind in Healthy in 60 participants. Completed in 15 September 2020.

Timeline

12 May 2020

Primary endpoint
15 September 2020

15 September 2020

Quick facts

Lead sponsor	Neurohacker Collective
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	60
Start date	12 May 2020
Primary completion	15 September 2020
Estimated completion	15 September 2020
Sites	1 location across United States

Drugs / interventions tested

Qualia Mind
Placebo

Conditions studied

Healthy — all drugs for Healthy →
Cognitive Function — all drugs for Cognitive Function →

Sponsor

Neurohacker Collective

Who can join

Adults 18 to 75, any sex, with Healthy or Cognitive Function. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, placebo-controlled, crossover study designed to investigate the safety and efficacy of Qualia Mind on cognition in a healthy adult population between ages of 18 and 75 years. Qualia Mind is a nootropic supplement containing a complex mixture of vitamins, minerals, amino acids, choline donors, and herbal ingredients. These components have been demonstrated to exert their cognitive effects through distinct mechanisms of action involving cholinergic, glutamatergic, and dopaminergic receptor signalling; neuroplasticity; and modulation of cell membrane structure and metabolism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04389723 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neurohacker Collective
Last refreshed: 9 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04389723.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing